medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2013, Número 1

<< Anterior Siguiente >>

Ann Hepatol 2013; 12 (1)


Patients younger than forty years old with hepatitis C virus genotype-1 chronic infection had treatment responses similar to genotype-2 infection and not related to interleukin-28B polymorphism

Chun-Yen L, I-Shyan S, Wen-Juei J, Chang-Wen H, Chien-Hao H, Ji-Yih C

Idioma: Ingles.
Referencias bibliográficas: 32
Paginas: 62-69
Archivo PDF: 117.30 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Marc GG, Doris BS, David LT, Leonard BS. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 2009; 49: 1335-74.

  2. Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol 2009; 24: 336-45.

  3. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 2609-17.

  4. Sanaa MK, Samer SEK, Michelle DS, Mohamed H, Imad NA, Mohamed M, et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response. Hepatology 2007; 46: 1732-40.

  5. Yu ML, Dai CY, Huang JF, Chiu CF, Yang YH, Hou NJ, et al. Rapid virological response and treatment duration forchronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008; 47: 1884-93.

  6. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44: 97-103.

  7. Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135: 451-8.

  8. Liu CH, Liu CJ, Lin CL, Liang CC, Hsu SJ, Yang SS, et al. Pegylated interferon-alpha-2a plus ribavirin for treatmentnaive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008; 47: 1260-9.

  9. Moreno C, Deltenre P, Pawlotsky J-M, Henrion J, Adler M, Mathurin P. Shortened treatment duration in treatmentnaive genotype 1 HCV patients with rapid virological response: A meta-analysis. J Hepatol 2010; 52: 25-31.

  10. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.

  11. Mangia A, Minerva N, Bacca D, Cozzolongo R, Ricci GL, Carretta V, et al. Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. Hepatology 2008; 47: 43-50.

  12. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola R, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357: 124-34.

  13. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment- induced viral clearance. Nature 2009; 461: 399-401.

  14. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O/’hUigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.

  15. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-[alpha] and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-9.

  16. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-4.

  17. Massard J, Ratziu V, Thabut D, Moussalli J, Lebray P, Benhamou Y, et al. Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol 2006; 44(Sup.1): S19-S24.

  18. Huang C-F, Yang J-F, Dai C-Y, Huang J-F, Hou N-J, Hsieh M-Y, et al. Efficacy and Safety of Pegylated Interferon Combined with Ribavirin for the Treatment of Older Patients with Chronic Hepatitis C. J Infectious Diseases 2010; 201: 751-9.

  19. Kainuma M, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, et al. Pegylated interferon alpha-2b plus ribavirin for older patients with chronic hepatitis C. World J Gastroenterol 2010; 16: 4400-9.

  20. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon £2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. The Lancet 1998; 352: 1426-32.

  21. Bedossa P. Intraobserver and Interobserver Variations in Liver Biopsy Interpretation in Patients with Chronic Hepatitis C. Hepatology 1994; 20: 15-20.

  22. Chen JY, Lin CY, Wang CM, Lin YT, Kuo SN, Shiu CF, et al. IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-[alpha] plus ribavirin therapy in Taiwanese chronic HCV infection. Genes Immun 2011; 12: 300-9.

  23. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.

  24. Afdhal NH, McHutchison JG, Zeuzem S, Mangia A, Pawlotsky JM, Murray JS, et al. Hepatitis C pharmacogenetics: State of the art in 2010. Hepatology 2011; 53: 336-45.

  25. O’Rahilly S, Spivey RS, Holman RR, Nugent Z, Clark A, Turner RC. Type II diabetes of early onset: a distinct clinical and genetic syndrome? Br Med J (Clin Res Ed) 1987; 294: 923-8.

  26. Lyssenko V, Almgren P, Anevski D, Orho-Melander M, Sjögren M, Saloranta C, et al. Genetic Prediction of Future Type 2 Diabetes. PLoS Med 2005; 2: e345.

  27. Ooi BS, Chen BT, Toh CC, Khoo OT. Causes of hypertension in the young. Br Med J 1970; 3: 744-6.

  28. Garrison RJ, Kannel WB, Stokes J, Castelli WP. Incidence and precursors of hypertension in young adults: The Framingham offspring study. Preventive Medicine 1987; 16: 235-51.

  29. Chen C-H, Chang T-T, Cheng K-S, Su W-W, Yang S-S, Lin HH, et al. Do young hepatocellular carcinoma patients have worse prognosis? The paradox of age as a prognostic factor in the survival of hepatocellular carcinoma patients. Liver International 2006; 26: 766-73.

  30. Lam CM, Chan AOO, Ho P, Ng IOL, Lo CM, Liu CL, et al. Different presentation of hepatitis B-related hepatocellular carcinoma in a cohort of 1863 young and old patientsimplications for screening. Alimentary Pharmacology & Therapeutics 2004; 19: 771-7.

  31. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for Untreated Chronic HCV Genotype 1 Infection. N Engl J Med 2011; 364: 1195-206.

  32. Lin CY, Chen JY, Lin TN, Jeng WJ, Huang CH, Huang CW, et al. IL28B SNP rs12979860 is a critical predictor for ontreatment and sustained virologic response in patient with hepatitis C virus genotype-1 infection. PLoS ONE. 2011.




2020     |     www.medigraphic.com